[Juguan 365] News on August 27
Wingtech's net profit in the first half of 2023 is 1.258 billion
Forward Medical completed the A round of financing
Dongfang Selection's transformation to live streaming e-commerce was successful
AI Teeth Whitening Company Picks One out of 10 Million Angel Rounds of Financing
Tesla's new Model 3 fully upgraded
Wingtech's net profit in the first half of the year was 1.258 billion
Wingtech Technology released the 2023 semi-annual report. During the reporting period, Wingtech achieved a revenue of 29.206 billion yuan, an increase of 2.49% year-on-year; a net profit of 1.258 billion yuan attributable to the parent company, an increase of 6.45% year-on-year, of which the net profit in the second quarter increased by 73.27% from the previous quarter.
In terms of semiconductor business, data shows that in the first half of the year, Nexperia Semiconductor achieved revenue of 7.639 billion yuan, a business gross profit margin of 41.3%, and a net profit of 1.388 billion yuan. Among them, the operating income in the first quarter and the second quarter was 3.797 billion yuan, 3.842 billion yuan, net profit was 660 million yuan and 728 million yuan respectively. Revenue and profit increased sequentially in the second quarter.
In addition, the financial report also disclosed that Nexperia further increased its own wafer and packaging production capacity and the proportion of outsourced manufacturing. In the first half of the year, its own European fab continued to expand production. At this stage, the fab has begun to import products, with a pass-through rate of over 95%, and has obtained ISO certification and automotive-level IATF16949 compliance certification.
Looking forward to the second half of the year, Wingtech Technology said that with the gradual recovery of the semiconductor and consumer electronics industries, it has become an industry consensus to get out of the bottom of the cycle, and the company's performance is expected to be further boosted.
Forward Medical completed the A round of financing
Daotong Investment announced that recently, Daotong Family enterprise—Shanghai Fuyi Medical Technology Co., Ltd. Shan China led the investment, and Daotong Investment continued to pursue investment. The funds raised will be mainly used to accelerate product line research and development, clinical trials, team expansion, R&D center construction and GMP workshops put into use.
Forward Medical was established in 2021 and is headquartered in Shanghai. It focuses on microsurgery above the head and neck. Using macro-micro-controlled humanoid dual-arm robots as a platform, it continues to create a product matrix of fully intelligent, high-precision, and anthropomorphic surgical robots. The core members of the team have senior experience in related fields such as surgical robot research and development, medical equipment industrial design, and medical venture capital market operations.
At the same time, Fuyi Medical has a strong scientific advisory system, and its advisory members include the world's top academicians in the field of surgical robots, first-class clinical experts, and investors from well-known medical venture capital institutions. The internal and external teams complement each other, and have formed a complete experience from clinical demand discovery, industrial design, robot research and development to clinical registration. With its lean technical strength and underlying innovation capabilities, the company has attracted widespread attention from the capital market.
Regarding this round of financing, Daotong Investment said: In less than two years since its establishment, Fuyi Medical has obtained multiple rounds of financing, which reflects the capital market's recognition of Fuyi's technological innovation capabilities. We were the earliest angel investors of Fuyi. At that time, we were interested in the company's innovative R&D capabilities. The design and development of microsurgical robots above the head and neck were extremely challenging. At the same time, we also saw huge market potential. We look forward to working with the company to do something for industrial innovation, and to popularize innovative technologies and apply them to unsatisfied markets.
Dongfang Selection's transformation to live streaming e-commerce was successful
Oriental Selection announced its full-year results for fiscal year 2023 from June 1 last year to May 31 this year. The total revenue from continuing operations increased by 651.0% from 600 million yuan in fiscal year 2022 to 4.5 billion in fiscal year 2023. Yuan. The net profit from continuing operations in fiscal year 2023 is 971 million yuan, turning losses into profits from a loss of 71 million yuan in fiscal year 2022.
Most of this huge growth is attributable to the strong development of self-operated products and live broadcast e-commerce business. The data shows that in fiscal year 2023, the total revenue of Dongfang Selection’s self-operated products and live broadcast e-commerce segment was 3.9 billion yuan, of which the total revenue of self-operated products exceeded 2.6 billion yuan.
In the fiscal year of 2023, Dongfang Selection’s annual GMV of goods will reach 10 billion yuan, and the GMV from Douyin accounts for the vast majority. The total number of paid orders for third-party products and self-operated products on Douyin is 136.3 million.
Yu Minhong, chairman of Oriental Selection Holdings Limited, said: "FY2023 marks the first year we have become a brand new company's own brand products and live broadcast e-commerce company under the name of 'Oriental Selection'."
AI Teeth Whitening Company Picks One out of 10 Million Angel Rounds of Financing
The AI teeth whitening solution provider [白里选一] recently announced that it has completed an angel round financing of 10 million yuan. This round of financing was led by Mr. Xiang Jin, a well-known dental industry professional. The financing funds will be mainly used for AI algorithm research and development, team expansion and the sales channel development of its "Beyke iWhite" AI teeth whitening solution products.
Bai Litiaoyi CEO Li Yu said: Mr. Xiang Jin has more than 20 years of management experience in the field of medical devices. In the oral medical device industry; during his tenure as the managing director of Align China, he led invisalign to achieve rapid business growth from tens of millions of RMB to nearly two billion RMB in eight years. Mr. Xiang Jin's investment not only supports the company's financial support, but also provides valuable experience for the company's strategic development.
Li Yu believes that the current application methods in the field of tooth whitening lack uniform standards, and there is no quantitative control system among the four aspects of tooth condition, whitening agent concentration, reaction time, and tooth whitening results, and the final treatment results cannot be predicted. Bailitiaoyi is committed to deploying AI reasoning of tooth whitening cases to finally form a treatment goal-oriented whitening product system.
According to public data, Chinese residents’ spending on dental care is only about one-fiftieth of that of the United States, and the annual per capita visits are only about one-third of that of the United States, which reflects that there are still a lot of gaps in China’s dental market . Many people who have oral problems and have the ability to pay have not yet entered the dental clinic. On the other hand, the clinic has invested a lot of manpower, material resources, and financial resources to compete for existing customers. Bai Litiaoyi uses the AI large-scale model to implement the personalized AI dental aesthetics and health assessment report, which provides a solution to stimulate the consumption potential of the Chinese dental market.
Tesla's new Model 3 fully upgraded
Recently, information about the upcoming arrival of Tesla's new Model 3 has aroused widespread concern in the industry. It is reported that Tesla's new Model 3 has ended the "trial production phase", and production promotion and stress testing will begin on August 25, or centralized delivery will begin at the end of September.
It is reported that starting from August 16, 2023, Tesla's offline stores have begun to accept reservations for the new Model 3, and the pricing is valid for 2 months, which means that the new Model 3 will be officially launched in September. release.
For users, the most anticipated part of the new Tesla Model 3 is likely to be the changes in intelligent driving assistance and the price, which is believed to be an important reason why it is more attractive to existing currency holders. In terms of price. It is reported that the price of the new Tesla Model 3 may be around 200,000 yuan based on successful cost control, and a further price drop may become a strong guarantee for the sales growth of the new Tesla Model 3.
Tesla's sales continued to rise in the first half of 2023, reaching 477,000 vehicles, a year-on-year increase of 61.7%. The release of the new Model 3 is expected to further boost sales growth, but it will also bring new sales pressure to Tesla. Therefore, Tesla may have to continue to reduce its selling price or reserve sufficient room for price reduction to remain competitive in a fiercely competitive market.
The information comes from the Internet and is for reference only
Organized by: Juguan 365
Unauthorized reprinting is prohibited